Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
A safety warning regarding the potential risk of suicidal ideation and behaviors associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.
The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, diminishing the efficacy of oral contraceptives could not be dismissed.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
According to the TGA's safety alert, updated product warnings have been issued for this class of prominent medications. These drugs are formally utilized in Australia for managing type 2 diabetes and obesity, and the update follows investigations conducted by international regulatory bodies.